A recent study indicates that GLP-1 weight-loss drugs may improve employment and relationship prospects for women, particularly those who were single or unemployed at the start of treatment. The research, independently published by Rebecca Diamond, a professor of economics at Harvard University, found that women who successfully lost weight with these medications experienced a 29% increase in marriage and cohabitation rates and a 27% rise in job prospects after about 18 months.
The study used data from the Understanding America Study, a panel survey conducted by the University of Southern California. Diamond compared women who began taking GLP-1 drugs for weight loss with those who wanted to start but had not yet done so. The analysis accounted for factors such as body mass, health, income, employment, partnership status, and well-being before treatment. Women taking GLP-1s for diabetes were excluded, as their use is driven by a medical condition rather than weight-loss demand.
Dr. Peter Balazs, a hormone and weight-loss specialist from New York and New Jersey who was not involved in the study, commented on the findings. He noted that the improvements appeared primarily in «new match» situations, such as job interviews or dating, rather than within existing jobs or relationships. «This says more about societal bias than it does about the medication itself,» Balazs told Fox News Digital. He added that his patients often report feeling more confident and «visible» after weight loss, which could translate into better interview performance and networking.
Dr. Krishna Vyas, a plastic surgeon at Blechman Plastic Surgery in New York, also not involved in the research, observed that many patients seek breast lifts or body contouring after significant GLP-1 weight loss, after which they find themselves «re-engaging with life.» He described the confidence effect as «real in the exam room.» However, the study showed no clear improvement in depression, loneliness, or life satisfaction, even as marriage and employment rates climbed dramatically. «The opportunities opened, yet the women didn't report feeling better, which suggests it was largely the gatekeepers who changed, not the women,» Vyas said.
Diamond argues that these findings suggest part of the «female obesity penalty» comes from how people are judged when being matched up, either in a new relationship or a new job. The study focused exclusively on women because they are more likely to use GLP-1s than men. Among women who were not employed at the start of the study, job prospects increased by 27% after about 18 months. However, those who were already employed did not display any clear upward progress in their careers.
The study has several limitations. Because it was an observational study rather than a randomized clinical trial, it could only show an association, not cause and effect. The findings are considered preliminary because the paper has not yet been peer-reviewed, the author acknowledged. Balazs noted that the focus on women introduces potential bias, and he expressed interest in seeing whether the findings would hold for men. Additionally, the information from participants was self-reported, and researchers were unable to determine whether those who found new jobs were earning more money.
«Even though GLP-1 users appeared to have better outcomes on paper, they did not report greater overall life satisfaction,» Balazs added. «That raises important questions about whether these external changes translate into meaningful improvements in well-being.» Fox News Digital reached out to the study researcher and multiple human resources organizations for comment but did not receive responses by the time of publication.
